Abstract: An objective of the present invention is to provide novel compounds which have inhibitory activity against autophosphorylation of an FGF receptor family and, when orally or intraveneously administered, can suppress the growth of cancer cells. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; Q represents NR10, CR11R2, carbonyl, O, S(?O)m, wherein m is 0 to 2, or urea; R1 to R3 each independently represent H, OH, halogen, nitro, amino, alkyl, alkoxy or the like in which the alkyl and alkoxy groups are optionally substituted; R4 represents H; R5 to R8 each independently represent H, halogen, alkyl, or alkoxy; and R9 represents an optionally substituted carbocyclic or heterocyclic group.

Abstract: A glass coating agent is provided which is adapted for application onto the surface of a glass substrate and, upon heating, forms a metal oxide layer. The glass coating agent comprises a metallic compound represented by formula (I): R1k-mM(OCOR2)m??(I) wherein M represents a metal atom selected from the group consisting of tin, titanium, indium, silicon, zirconium, and aluminum; R1 represents a straight-chain, branched, or cyclic alkyl, alkenyl, or aryl group having 1 to 6 carbon atoms; R2 represents a branched alkyl group having 3 to 6 carbon atoms; k is a number representing the valence of the metal atom M; and m is a number of 1 to k. Further, there is provided a glass coating method using the glass coating agent. According to the glass coating agent, a metal oxide layer having excellent fastness properties and free from haze can be formed on the surface of glass substrates. According to the glass coating method, the metal oxide layer can be continuously and stably produced.

Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.

Abstract: This invention provides: a therapeutic agent for graft rejection, graft-versus-host disease, autoimmune disease, allergic disease, or other diseases comprising dendritic cells (DCs) induced under culture conditions comprising both IL-10 and TGF-&bgr; or DCs prepared by adding inflammatory stimulation (e.g., TNF-&agr; or LPS) to the aforementioned DCs and, if necessary, an antigen associated with a target disease; a method of inducing human immunoregulatory dendritic cells by culturing human dendritic cells or their precursor cells in vitro with cytokines comprising at least IL-10 and TGF-&bgr;; human immunoregulatory dendritic cells obtained by such method; and a pharmaceutical composition comprising such human immunoregulatory dendritic cells.

Abstract: The production of carotenoid is accomplished using a DNA molecule that encodes a polypeptide as obtained from Haematococcus pluvialis, Phaffia rhodozyma, or Saccharomyces cerevisiae, having isopentonyl pyrophosphate (IPP) isomerase activity, or DNA molecule having a nucleotide sequence that hybridizes thereto. In particular, one can introduce such a DNA molecule into a carotenoid-producing microorganism, culture the microorganism thus transformed, and then obtain carotenoids in the culture broth and cells.

Abstract: An object of the present invention is to provide compounds having potent antitumor activity. The compounds according to the present invention are compounds represented by formula (I) or pharmaceutically acceptable salts or solvates thereof: wherein X and Z represent CH or N; Y represents O or S; R1, R2, and R3 represent H, alkoxy or the like; R4 represents H; R5, R6, R7, and R8 represent H, halogen, alkoxy or the like; R9 and R10 represent H, alkyl or the like; and R11 represents optionally substituted azolyl.

Abstract: An object of the present invention is to provide compounds having potent antitumor activity.

Abstract: An endo-&bgr;-N-acetylglucosaminidase gene encoding the following protein (a) or (b): (a) a protein comprising the amino acid sequence represented by SEQ ID NO: 3; and (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 3 by deletion, substitution, or addition of at least one amino acid and having the activity of endo-&bgr;-N-acetylglucosaminidase.

Abstract: An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis.

Abstract: A plastic container has a diamond like carbon film 20b formed on the inner surface of the container 20 made of plastic material 20a. The thickness of the diamond like carbon film 20b is within a range from 0.05 to 5 &mgr;m. The container 20 coated with the diamond like carbon film can be used for a returnable bottle for beverage.

Abstract: An object of the present invention is to provide compounds which have antitumor activity and do not change cytomorphosis. Disclosed are compounds represented by formula (I) and a pharmaceutically acceptable salts and solvates thereof and pharmaceutical compositions comprising said compounds: wherein X and Z each independently represent CH or N; R1 to R3 represent H, substituted alkoxy, unsubstituted alkoxy or the like; R4 represents H; R5 to R8 represent H, halogen, alkyl, alkoxy, alkylthio, nitro, or amino, provided that R5 to R8 do not simultaneously represent H; R9 and R10 represent H, alkyl, or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl, or aralkyl.

Abstract: The present invention relates to a a glassy-film forming coating agent, a method of coating a substrate with the a glassy-film forming coating agent, a bottle coated with the glassy-film forming coating agent, and a coating system for coating a substrate with the glassy-film forming coating agent.

Abstract: An objective of the present invention is to provide NKT cell-activating agents, therapeutic agents for autoimmune diseases (for example, systemic lupus erythematosus, systemic sclerosis, ulcerative colitis, encephalomyelitis, multiple sclerosis and human type I diabetes), and abortifacients. The medicinal compositions according to the present invention comprise &agr;-glycosylceramides of the following formula (I), or a salt or a solvate thereof as an active ingredient.

Abstract: The specification relates to a method for producing a chimeric non-human animal, which comprises preparing a microcell containing a foreign chromosome(s) or a fragment(s) thereof and transferring the foreign chromosome(s) or fragment(s) thereof into a pluripotent cell by fusion with the microcell; a chimeric non-human animal which can be produced by the above method and its progeny; tissues and cells derived therefrom; and a method for using the same. Further, a pluripotent cell containing a foreign chromosome(s) or a fragment(s) thereof, a method for producing the same, and a method for using the same are also provided. Moreover, a pluripotent cell in which at least two endogenous genes are disrupted, and a method for producing the same by homologous recombination are provided.

Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human and mouse secreted stem cell growth factor-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries prepared from mouse bone marrow and human fetal liver spleen, ovary, adult brain, lung tumor, spinal cord, cervix, ovary, endothelial cells, umbilical cord, placental, lymphocyte, lung fibroblast, fetal brain, and testis. Other aspects of the invention include vectors containing processes for producing novel human secreted stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.

Abstract: A object of the present invention is to provide a peptide inhibiting tumorigenesis or metastasis. The present invention is a peptide or derivatives thereof comprising a modified amino acid sequence of Protein Kinase N having the activated Rho protein binding activity and not having protein kinase activity, and a peptide or derivatives thereof comprising a modified amino acid sequence of Protein Kinase N inhibiting the protein kinase activity of Protein Kinase N or the enhancement of the activity and not having protein kinase activity.

Abstract: A plastic container has a diamond like carbon film 20b formed on the inner surface of the container 20 made of plastic material 20a. The thickness of the diamond like carbon film 20b is within a range from 0.05 to 5 &mgr;m. The container 20 coated with the diamond like carbon film can be used for a returnable bottle for beverage.

Abstract: A plastic container has a diamond like carbon film 20b formed on the inner surface of the container 20 made of plastic material 20a. The thickness of the diamond like carbon film 20b is within a range from 0.05 to 5 &mgr;m. The container 20 coated with the diamond like carbon film can be used for a returnable bottle for beverage.

Abstract: A chimeric, non-human animal can be produced by a method that entails providing a microcell that contains one or more foreign chromosomes or fragment(s) thereof and then fusing the microcell with a pluripotent cell, thereby introducing the foreign chromosome(s) or fragment(s) into the latter. The pluripotent cell thus obtained can be used to generate a chimeric, non-human animal, the cells, tissues, and/or progeny of which can be the source of a product, such as an antibody, that is associated with one or more genes on the foreign chromosome(s) or fragment(s).

Abstract: An object of the present invention is to provide a vector which can be integrated into a yeast chromosome in a high number of copies. Another object of the present invention is to provide a modified vector which can be integrated into the yeast chromosome in a high number of copies and of which expression units stably maintain on the chromosome. The vector according to the present invention comprises a marker gene for selecting transformants, a shortened promoter sequence which is operably linked to the marker gene and a sequence homologous to the chromosomal DNA of Candida utilis, and optionally a heterologous gene or a gene derived from C. utilis, wherein the vector is linearized by cleaving within said homologous DNA sequence or at both ends of the homologous DNA sequence with restriction enzymes, and wherein the heterologous gene or the gene derived from C. utilis can be integrated into the chromosomal DNA of C. utilis by homologous recombination.